Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gan and Lee PharmaceuticalsSHSE:603087 -2.27%89 Current Ratio is 6.91 as of Jun. 2026, which is 13% below its 10-year median of 7.98. GuruFocus rates SHSE:603087 with a GF Score™ of 89/100 and a GF Value™ of ¥73.06 (Fairly Valued). The stock has 5 warning signs investors should review. Among 850 Medical Devices & Instruments companies, Gan and Lee Pharmaceuticals ranks better than 86.59% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Gan and Lee Pharmaceuticals's current ratio for the quarter that ended in Jun. 2026 was 6.91.
Gan and Lee Pharmaceuticals has a current ratio of 6.91. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Gan and Lee Pharmaceuticals's Current Ratio or its related term are showing as below:
SHSE:603087'
s Current Ratio Range Over the Past 10 Years
Min: 4.73 Med: 7.98 Max: 18.9
Current: 6.91
During the past 13 years, Gan and Lee Pharmaceuticals's highest Current Ratio was 18.90. The lowest was 4.73. And the median was 7.98.
SHSE:603087's Current Ratio is ranked better than 86.59% of 850
companies
in the Medical Devices & Instruments industry
Industry Median: 2.43
vs SHSE:603087: 6.91
Gan and Lee Pharmaceuticals (SHSE:603087) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Gan and Lee Pharmaceuticals Current Ratio Related Terms
Gan and Lee Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603087 vs ISRG, BDX, RMD: Current Ratio Comparison
For the Medical Instruments & Supplies subindustry, Gan and Lee Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gan and Lee Pharmaceuticals Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gan and Lee Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Gan and Lee Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gan and Lee Pharmaceuticals (SHSE:603087) has a Current Ratio of 6.91 as of Jun. 2026. This is 13% below median its historical median of 7.98. Over the past decade, Gan and Lee Pharmaceuticals' Current Ratio has ranged from 4.73 to 18.90. According to the industry distribution chart, Gan and Lee Pharmaceuticals ranks #114 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 13.4%.
Is Gan and Lee Pharmaceuticals' Current Ratio too high?
Gan and Lee Pharmaceuticals' current Current Ratio of 6.91 is 13% below median its 10-year median of 7.98. Over the past 10 years, this metric has ranged from a low of 4.73 to a high of 18.90. The Medical Devices & Instruments industry median Current Ratio is 2.43. Gan and Lee Pharmaceuticals' value of 6.91 is 184.4% above this industry median. Based on the distribution chart, Gan and Lee Pharmaceuticals ranks #114 out of 850 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Gan and Lee Pharmaceuticals has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gan and Lee Pharmaceuticals' Current Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gan and Lee Pharmaceuticals ranks #114 out of 850 companies for Current Ratio. This places Gan and Lee Pharmaceuticals in the top 13% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.43. Gan and Lee Pharmaceuticals' value of 6.91 is 184.4% above this benchmark. Historically, Gan and Lee Pharmaceuticals' own Current Ratio has ranged from 4.73 to 18.90 over the past decade. While the company's 10-year median is 7.98 vs. the industry median of 2.43, Gan and Lee Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.43, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gan and Lee Pharmaceuticals's current Current Ratio of 6.91 is 184.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gan and Lee Pharmaceuticals's current Current Ratio is 6.91, which is 13% below median its own 10-year median of 7.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gan and Lee Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals (SHSE:603087) is currently considered Fairly Valued. The stock's GF Value™ is ¥73.06, compared to a current price of ¥66.34 — trading 9.2% below its estimated fair value. The current Current Ratio is 6.91, which is 13% below median its 10-year median of 7.98 and 184.4% above the Medical Devices & Instruments industry median of 2.43. Gan and Lee Pharmaceuticals' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Gan and Lee Pharmaceuticals (SHSE:603087), the current Current Ratio is 6.91 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gan and Lee Pharmaceuticals (SHSE:603087) Overvalued in 2026?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals stock appears to be undervalued.
The current stock price of ¥66.34 is trading 9.2% below its estimated GF Value™ of ¥73.06.
GuruFocus considers Gan and Lee Pharmaceuticals to be Fairly Valued.
Key valuation signals for SHSE:603087:
Current Ratio: 6.91 (13% below median its 10-year median of 7.98)
GF Value™: ¥73.06 vs. price of ¥66.34 (9.2% below fair value)
Industry Position: 184.4% above the Medical Devices & Instruments median (#114 of 850)
No single metric tells the full story. See the SHSE:603087 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603087 has been successfully added to your 
